• Hub Login
  • Contact
  • Investors
  • Viveve Solutions
    • Viveve System
    • InControl by Viveve
  • Clinical Studies
  • About
    • Mission
    • Leadership
    • Careers
  • News
    • Blog
    • Media & Press
    • Investor News
    • Events
  • Testimonials
Select Page
Dev Site

A Global Women’s Intimate Health Company

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Clinical Advisory Board
    • Medical Consultants
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts

Viveve to Present at Cowen and Company 39th Annual Health Care Conference

Mar 5, 2019

Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

Jan 16, 2019

Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

Jan 3, 2019

Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

Dec 20, 2018

Viveve Announces Closing of Public Offering of Shares of Common Stock

Dec 11, 2018

Viveve Announces Pricing of Public Offering of Shares of Common Stock

Dec 6, 2018

Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

Dec 6, 2018

Viveve Announces Proposed Public Offering of Shares of Common Stock

Dec 6, 2018

Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

Nov 29, 2018

Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

Nov 15, 2018
RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...30

    Solutions

    • Viveve System
    • InControl Products
    • Common Conditions

    About

    • Mission
    • Leadership
    • Contact Us
    • Investor Information

    News

    • Viveve Blog
    • Events
    • News & Publications
    • Testimonials

    Resources

    • Hub Login
    • Careers with Viveve
    • Support Center
    Dev Site
    345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112
    The Viveve® System is an internationally patented cryogen-cooled, monopolar radiofrequency (CMRF) energy-based device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan. Country-specific approved indications include: • In Argentina the Viveve System is indicated for the treatment of urinary incontinence, vaginal laxity, and sexual function. • In Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Mexico, Panama, Philippines, Singapore, Uruguay, and Venezuela the Viveve System is indicated for the treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function. • In the EU, Bahrain, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, South Africa, Switzerland, and Ukraine the Viveve System is indicated for the treatment of vaginal laxity. • In Peru, Taiwan, and the United States the Viveve System is cleared for general surgical procedures for electrocoagulation and hemostasis.